INC Research

INC Research completes acquisition of Kendle International

Wednesday, July 13, 2011 10:31 AM

Raleigh, N.C.-based INC Research, a therapeutically focused CRO privately held by Avista Capital Partners and Ontario Teachers’ Pension Plan, has completed the acquisition of Kendle International in an all-cash transaction with a total equity value of approximately $232 million or $15.25 per share.

More... »

INC Research names Chris Smyth senior vp, clinical development

Wednesday, June 29, 2011 11:10 AM

Raleigh, N.C.-based INC Research, a therapeutically focused CRO has appointed Chris Smyth, Ph.D., MBA, to its oncology leadership team as senior vice president, clinical development.

More... »

INC Research acquires Australian CRO Trident

Friday, June 3, 2011 01:36 PM

Raleigh, N.C.-based INC Research, a therapeutically focused CRO, has acquired Australian CRO Trident Clinical Research to expand its clinical trials outsourcing footprint and expertise in Australia, New Zealand and India.

More... »

INC Research to acquire Kendle in all-cash deal to help compete for strategic deals with big pharma

Monday, May 9, 2011 09:38 AM

After months of rumors about Kendle International being on the block, CRO INC Research late last week announced it would buy the mid-tier publicly held CRO in an all-cash transaction. If the deal goes through, Kendle will be taken private.

More... »

INC Research to acquire Kendle International

Thursday, May 5, 2011 01:24 PM

INC Research, a therapeutically focused global CRO privately held by Avista Capital Partners and Ontario Teachers' Pension Plan, and CRO Kendle International, have jointly announced a definitive merger agreement. Raleigh, N.C.-based INC Research will acquire Kendle in an all-cash transaction with a total equity value of approximately $232 million.

More... »

Patrick Melvin joins oncology leadership team at INC Research

Tuesday, March 1, 2011 08:00 AM

CRO INC Research has named Patrick Melvin executive director, Oncology. He will be using his hematology/oncology trial experience for phase I first-in-man studies through pivotal global phase IV programs.

More... »

RPS to Raise $100 Million in IPO

Wednesday, June 23, 2010 08:15 AM

ReSearch Pharmaceutical Services (RPS) plans an initial public offering in the U.S. on the Nasdaq exchange. The Fort Washington, Pa.-based contract research organization (CRO ) seeks to raise $100 million from the IPO.

More... »

INC Research Provides ePRO Services Through Invivodata Partnership

Friday, March 12, 2010 06:34 AM

Raleigh, N.C.-based CRO  INC Research added electronic patient reported outcomes (ePRO) services to its offerings through a partnership with ePRO provider invivodata. Prior to the formation of the strategic partnership, the two companies collaborated on multiple international clinical trials.

More... »

INC Research Launches Alliance Partnerships Program

Wednesday, February 24, 2010 06:45 AM

Raleigh, N.C.-based CRO INC Research launched an alliance partnerships program to create and manage strategic alliances with pharmaceutical and biotech customers. The company said it hopes to create relationships with customers based on joint strategic objectives rather than service agreements.

More... »

Dedicated Phase I Appoints New CMO

Friday, June 26, 2009 10:54 AM

Dedicated Phase I in Phoenix, Ariz., named a new chief medical officer to head its 80-bed phase I clinical research facility. Clark Springgate, M.D., Ph.D., brings more than 25 years' experience to the organization, having directed and participated in more than 256 clinical trials, including first-in-man and first-in-therapeutic-class studies.

More... »